From my perspective and IMO, Where are we going? What is

New Post Public Reply Private Reply Replies (4) Message Board
MGK_2
729
From my perspective and IMO, Where are we going? What is all this leading to?
When Amarex begins to draw to a close, to a conclusion, some of Big Pharma will become more comfortable with CytoDyn, with Leronlimab. Big Money like Blackrock and Vanguard becomes more comfortable with going long CYDY and not so head long on shorting it. Big Media begin producing pro-CYDY articles and report factual, non-distortive information on CytoDyn and Leronlimab. The FDA approves Leronlimab.



When Amarex resolves, the FDA is comfortable with CytoDyn and many Big Pharma approach CytoDyn wanting to partner. They see Leronlimab's capacity to augment the functionality of their drug and ask CytoDyn to consider combination therapy for their indication. This becomes Big Pharma's only chance in escalating their drugs to the next level in the new era of enlightenment. Otherwise, they fail. Partnership with CytoDyn, in combination therapy with Leronlimab becomes their saving grace.

//

Given that Amarex is arbitration, it shouldn't go on for years. I'm giving it about a year from when it began, to about November or December, 2022. But it is very complicated. I don't know how deep Sidley Austin wants to take this. I don't know how much of a settlement they will be happy with. I don't know how easy are the pickins. I don't feel they will be happy with settling for less than a billion, so they may drag it on until they can get that, but I don't think they will continue to pursue the matter so long to extract its full worth of probably $20 billion.

So far so good. No discussion that arbitration is off course, therefore, I put it on course. Justice must be done. Judgement is coming. SA won't stop till justice comes to pass. The conclusion of the Amarex arbitration brings about a new era in pharmaceutical therapy, LL approval, FDA clearance and multiple BP partnerships in combination with Leronlimab.

//

What is Justice? Who did wrong? Was it only Amarex? Who collaborated with them? Will another pharmaceutical be implicated? Will Big Money be implicated? Will anyone rat on the other? Will anyone stand for CytoDyn? Will anyone agree that the BLA was sabotaged? Will anyone testify that the trials were botched or poorly documented? Will anyone bring about these details and clearly reveal what actually happened? Will the outcome of the Amarex arbitration set the record straight? What will be the main outcome after this arbitration is resolved? Would it be to reveal that Amarex was a pitiful CRO who couldn't write a BLA to save its life? (I think not.) or Would it be to reveal how a certain Pharma or a group of Pharmaceuticals and/or Big Money fear the FDA approval of Leronlimab given a successful combination trial of LL with HAART for HIV, with a p value of 0.0032.

From Wiki:
Quote:
In the pivotal trial of Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients, 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. (where as ONLY with) Recent approved drugs for this population range from ONLY 43% after 24 weeks to ONLY 45% after 48 weeks with viral load suppression of < 50 cp/mL.


CytoDyn knew they had this in the bag. Everything had been lined up. Manufacturing. Salesforce. Distribution. Even Amarex said they will have the BLA submitted on time.

The only way this Big Entity had to block the approval of LL was to trip up the third part of this BLA submission and how else to do that but by sabotaging the BLA by colluding with the entity writing the Document who was the CRO, Amarex. How did they get the CRO/Amarex to submit a pathetic and cringeworthy document?

All of this is what Sidley Austin is set out to determine. How long will this drag out? What are the consequences if these multiple factions and entities do not oblige Sidley Austin? Delays and delays and it depends on the interactions between the entities involved. Some will push to get this resolved. I feel it will finish near end of year 2022.

Who put up the necessary $6.5 million bond to carry this arbitration out? David Welch put up this bond, out of his confidence and conviction in the matter. Whoever or whatever group/entity it was that colluded with Amarex to commit this deed against us, it should always be remembered that it was David Welch that has prevented this entity from doing it to us again, because, it will never happen again as a result of this arbitration which he stood for.

//

The addition of Dr. Paul Edison, Dr. Kabir Mody, Dr. Otto Yang and Dr. Jacob Lalazari, which potential CEO candidate would not be proud of such a list of experts to help him make his decisions? Doesn't the addition of this team of experts facilitate the search for an experienced and qualified CEO?

What if Amarex arbitration conclusion and the new CEO come together? I already said FDA comfort zone comes with Amarex concluding and then compounding that with a new qualified CEO... what do you have? CytoDyn grows big because many Big Pharma will have no chance without LL. Who ever is not against us is for us. Many will choose to join us. Yet, many will choose to fight this war with old tactics of deceit and usury, paying off the approving party for rapid approval, using inept, sub-par weapons of partial effectiveness, using all they and whatever they have and whoever would help them to beat us, still yet employing big money & big media but proving futile; however, many will leave those tactics and will rather choose a better way, leading to their success and to ours. Yes, the battles will continue.

//

You will have no need to be told that the times for CytoDyn have changed. It will be crystal clear. With the ending of Amarex and the completion of our board with new CEO, a new era begins in pharmaceutical treatments. A revelation will come over the people of the massive deceit which goes on in this industry. An understanding of the corruption and greed will grow. Clear evidence of clean effectual medicine being purposely thwarted and hindered pervades the atmosphere, the air waves. Understanding of disease pathways and mechanism of actions that confuse and render those diseases as inconsequential becomes paramount. People will wake the flapjacks up, people will become wiser. You will see this happen. Many companies are persuaded and pursue the ways of the people. They begin to pursue this new found understanding. But, many will hold fast to the old ways. But a division will be clear as day. A new age approaches and I feel humanity will survive it with CytoDyn leading, while Big Pharma and all of the other Bigs wither away, diminishing in battle.

1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating Builder-Ready Land: Avoid Costly Pitfalls

Updated Category News Views 18

Understanding the 'Builder-Ready' Label The term 'builder-ready' isn't as straightforward as it seems, especially when you're eye-balling land listings in rural areas. Cindy Garvey, a rural land expert, breaks down the frequent pitfalls buyers encounter when this label gets tossed around without much scrutiny. Utility Access Misconceptions Think utility access is a given?...

Continue Reading
UP Fintech Faces Major Class Action Amid Chinese Regulatory Hurdles

Updated Category News Views 133

Legal Battles Loom Over UP Fintech UP Fintech Holding Limited, trading under NASDAQ: TIGR, is knee-deep in legal mire, thanks to a hefty class action lawsuit. Levi & Korsinsky rings the legal bells for shareholders who grabbed TIGR securities from April 22, 2024, to June 2, 2026. The heat is on—a December 28, 2026 deadline for lead plaintiff spot beckons. Dust off those...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 68

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
Freedom Bank Taps McIntyre as CRE Powerhouse Leader

Updated Category News Views 77

Dan McIntyre's latest move to Freedom Bank of Virginia as Senior Vice President screams strategy. This isn’t just another shuffle of executive chairs—it’s a calculated play to deepen their roots in the fiercely competitive Washington D.C. real estate market. Now, why should investors like you sit up and take notice? Well, when a bank with hefty capital and a yawning...

Continue Reading
Gastops and Anschütz: Boosting Canada's Submarine Project

Updated Category News Views 62

New Partnership on the Horizon for Canada’s Submarines In today's world, where defense contracts become the dance of global players, Gastops and Anschütz have clasped hands to join the orchestra. The news blew in from EURONAVAL 2026, where these two powerhouses in condition monitoring and missile systems, respectively, inked a fresh Memorandum of Understanding to back...

Continue Reading
Kendra Scott's 'Long Live Joy' Campaign Dazzles

Updated Category News Views 40

Unveiling a Holiday Spectacle: 'Long Live Joy' Party hats off, folks, because Kendra Scott is stepping up the holiday game with something they’re calling 'Long Live Joy'. Now, we're not just talking about any run-of-the-mill marketing fluff. This one’s big, it’s colorful, and it’s here to make your accessorized holidays a tad more enchanting. The Multi-Faceted...

Continue Reading
SK Bio Pushes FDA Approval for Cenobamate in Seizures

Updated Category News Views 66

Taking New Strides in Epilepsy Treatment Today, we’ve got SK Biopharmaceuticals banging on the FDA’s door with a pile of paperwork. They’re pushing for the green light on cenobamate to tackle primary generalized tonic-clonic (PGTC) seizures, plus expand its use to pediatric patients with the focal-onset seizure condition. Now, if you think it sounds like a big...

Continue Reading
Lemonade Renters Insurance Expands Nationwide with MN

Updated Category News Views 38

Lemonade Finally Goes Full Circle Shake things up and ask yourself: When was the last time an insurance company made news for completing something big? Now, Lemonade (NYSE: LMND) just landed itself a headline by launching its renters insurance in Minnesota. With this move, it’s rounded off its offer across all 50 states plus Washington, D.C. Hitting that nationwide...

Continue Reading
Hugel's Sales Climb Despite Changes in Sales Models

Updated Category News Views 117

Hugel's Financial Fortunes in a Shifting Landscape Who would've thought? That’s the vibe hugging the numbers Hugel Inc. just dropped. Their performance for the first three quarters of 2026 is in the books, and results show consolidated net sales climbing 15% year-on-year. Just how did they pull this rabbit out of the hat? Let's dissect this a bit. Cracking the Code of...

Continue Reading
Nutramax Boosts Young Scientists with Lindau Sponsorship

Updated Category News Views 68

Nurturing the Next Generation with Nobel Insights If you think science is just numbers and facts, you'd better wrap your head around what Nutramax Laboratories is pulling off. The company sent five bright-eyed young scientists to the 75th Lindau Nobel Laureate Meeting in Germany, where minds sharper than a new scalpel gather to shape the frontiers of research. This isn't...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminerie Alouette Announces Major Investment in Aluminum Production

Updated Category News Views 425

Aluminerie Alouette's $1.1 Billion Commitment to Aluminum Industry Aluminerie Alouette, Canada's premier aluminum smelter, has made headlines with its significant investment of CA$1.5 billion (approximately $1.1 billion) aimed at transforming its operations in northern Québec. This strategic move positions the company as a pivotal player, especially concerning the U.S....

Continue Reading
BigBear.ai Faces Class Action Suit: Investor Rights at Stake

Updated Category News Views 234

Understanding the Class Action Suit Against BigBear.ai Investors should be aware of the ongoing class action lawsuit involving BigBear.ai Holdings, Inc. (NYSE: BBAI). The law firm Bronstein, Gewirtz & Grossman, LLC is guiding potential class members through the intricacies of this legal battle. This lawsuit addresses allegations of substantial damages concerning the...

Continue Reading
Stretch Zone Expands Footprint with New Location Opening

Updated Category News Views 593

Stretch Zone Opens New Location in West Reading Stretch Zone, renowned as the nation's leading assisted-stretching franchise, is excited to announce its latest studio opening in West Reading. This marks a significant milestone as the 393rd location in the U.S., led by new franchise owner Devvin Earnest. Devvin Earnest: A Journey to Owner Devvin's journey into the world of...

Continue Reading
Meta Implements Global Ban on Russian State Media Networks

Updated Category News Views 119

Meta's Decision to Ban Russian State Media Meta, the company behind Facebook (NASDAQ: META), recently made a significant policy change regarding Russian state media networks. This decision arises amid increasing concerns about misinformation and foreign influence on social media. The Networks Affected The ban includes networks such as RT and Rossiya Segodnya, which have...

Continue Reading
Sika's Strategic Acquisition in the Nordic Mortar Market

Updated Category News Views 289

Introduction to Sika's Latest Acquisition Sika, a leader in the specialty chemicals industry, has recently made strategic headlines by acquiring Marlon Tørmørtel A/S. This company is recognized for its outstanding mortar products and stellar customer service in the Nordic region. About Marlon Tørmørtel A/S Marlon Tørmørtel A/S stands out as a family-owned business...

Continue Reading